Carl Pinksy, MD, chief medical officer of the National Cancer Institute's biological response modifier program, to VP-medical affairs. Pinsky assisted in the design of the firm's first clinical trial of its Prosorba column in 1983, when he was with Memorial Sloan-Kettering.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."